GlassScriptPhysician profile
Stefanie Meredith
NPI 1740577279
$5,411.95
in general payments reported to CMS, 2019-2025
36 companies · $970 in 2025
The $970 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $964 · 2020: $272 · 2021: $75.74 · 2022: $616 · 2023: $820 · 2024: $1,693 · 2025: $970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,475 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,475.30 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,362.03 | 2022-2025 | |
| Lilly USA, LLC | $695.22 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $438.50 | 2019-2025 | |
| Novo Nordisk INC | $422.16 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $339.51 | 2019-2025 | Airsupra |
| Otsuka America Pharmaceutical, INC. | $302.16 | 2022-2024 | Rexulti, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $238.73 | 2019-2025 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $209.97 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $174.44 | 2019-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Medtronic, INC. | $151.60 | 2023-2024 | Intellis Adaptivestim, Interstim |
| Supernus Pharmaceuticals, INC. | $139.41 | 2022-2024 | Qelbree |
| Astellas Pharma US INC | $136.66 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $116.90 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $71.52 | 2022-2024 | |
| Dexcom, INC. | $60.86 | 2022-2023 | Dexcom G6 Transmitter |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefanie Meredith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.